Xianruida Medical-B (06669) announced interim results, net loss of 808.33 million yuan, year-on-year profit and loss

According to the Zhitong Finance App, Xianruida Medical-B (06669) announced its 2026 interim results, with revenue of about 332 million yuan, a year-on-year decrease of 5.6%; gross profit of about 233 million yuan, a year-on-year decrease of 10.5%; loss of 808.33 million yuan, a year-on-year profit to loss; and a loss of 0.27 yuan per share.

In terms of product commercialization, the company entered into a distribution agreement with BSC Group covering: (i) peripheral DCB products in overseas markets (including ACoArt Orchid®, ACoArt Tulip®, and AcoArt Litos®); (ii) peripheral radio frequency ablation systems in the US and Hong Kong, China; and (iii) coronary products in mainland China (including extension, AcoArt Camellia® and AcoArt Canna®). By the end of the reporting period, these products had been launched in more than 20 countries around the world through the BSC Group's commercial network. Looking ahead, the company will continue to promote global product registration as planned, and will actively explore opportunities to expand cooperation to a wider range of products.

In terms of R&D, the company entered into an R&D service agreement with BSC Group in 2025 to regulate cooperation between the two parties. According to the agreement, the company is responsible for the development, supervision and registration of jointly developed products, and BSC Group has commercialization rights after obtaining approval for listing. By the end of the reporting period, three R&D projects had been initiated.